About ECCO
ECCO General Assembly
ECCO Governing Board
The Council of National Representatives
Solidarity for Ukraine
ECCO Operational Board / Committees
Committee Podcasts
Affiliate ECCO Societies & ECCO Partners
ECCO Office
ECCO Disclosures
ECCO Elections
Congresses & Events
Future
19th Congress of ECCO 2024 - Stockholm
Past
18th Congress of ECCO 2023 - Copenhagen
Event Calendar
Quality Assurance/Endorsement
Congress Statistics
Membership
Individual Membership
Country Members
Corporate Membership
Affiliate ECCO Societies
Education
E-QUALITY
e-CCO Learning
Educational Workshops
Congress Educational Programme
IBD Nurse Education Programme
Y-ECCO Mentorship Forum
Letters from the e-Learning Ambassador
Science
UR-CARE
The Reviewers of ECCO
The Reviewers of 2022
Fellowships and Grants
ECCO Young Researcher Award
Scientific Workshops
Research Projects
BIOCYCLE Dissemination Workshops
ECCO CONFER Cases
Job postings
Publications
JCC
ECCO Guidelines
ECCO Topical Review
ECCO Position Statements
ECCO Scientific Workshop Papers
ECCO News
ECCO IBD App
ECCO Congress Abstracts
Surveys
Other publications
COVID-19
20years Anniversary Book
eNewsletter
Search
Author
Title
Category
Choose
Abstracts 2023
Abstracts 2022
Abstract 2021
Search
Clear
Poster presentations: Clinical: Therapy and Observation 2022
P283 Infliximab re-challenge: could it be an option in refractory IBD patients?
P284 Prophylactic medication for the prevention of endoscopic recurrence after ileocolonic resection in Crohn’s disease: a prospective study based on clinical risk stratification
P285 Longitudinal single cell transcription profiling of peripheral blood disentangles shared and biologic-specific patterns of early remission in active IBD patients
P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open
P287 The knowledge and skills needed to perform intestinal ultrasound – An international Delphi consensus survey
P288 Recurrence rates of advanced neoplasia after endoscopic or surgical resection in Inflammatory Bowel Disease patients: a retrospective cohort study
P289 Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project.
P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
P291 Effect of the preconception steroid-free remission period on disease activity during pregnancy and birth outcomes in women with Ulcerative Colitis: a retrospective cohort study
P292 Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis.
P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe
P294 On the way to disease control: Fatigue as part of a novel composite endpoint in an analysis of a prospective open label observation trial
P295 Proctitis during Crohn's disease, would it be a factor in the sustainability of anoperineal fistulas ?
P296 vedolizumab Does Not Increase Risk of Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease Using vedolizumab: a Retrospective Cohort Study
P297 Treatment of patients with complex perianal Crohn's disease with darvadstrocel: a single-institution real life experience.
P298 Pregnancy in Crohn's and Colitis - Observations, Levels and Outcomes Extension (PICCOLO-X) Study: Biological therapy reduces faecal calprotectin and the need for corticosteroids in pregnant women with Inflammatory Bowel Disease
P299 Prediction model for steroid-free clinical remission with vedolizumab at week 22 in patients with Ulcerative Colitis: Machine learning using clinical data at baseline
P300 Very early onset Inflammatory Bowel Diseases: Review of the Genoa-Messina joint clinical experience. Therapeutic approach: Part II
P301 Relapse rates after withdrawal of thiopurines in patients with Inflammatory Bowel Disease.
P302 Malignancy surveillance in patients with primary sclerosing cholangitis and Inflammatory Bowel Disease – keeping up with international guidelines? A Norwegian cohort study
P303 Biologic Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease: Are we aiming high?
P304 Intensified versus conventional infliximab induction in acute severe steroid-refractory Ulcerative Colitis
P305 Low ALT is more Common in Patients with IBD than Healthy Controls and is Associated with Active Disease
P306 Efficacy and tolerance of sodium picosulfate preparation in bowel Magnetic Resonance Imaging in Crohn’s disease
P307 The effect of COVID-19 infection and vaccination in patients with Inflammatory Bowel Disease and Irritable Bowel Syndrome.
P308 Quadruple oral antibiotic treatment in refractory Paediatric Inflammatory Bowel Disease – incidence and analysis of responders from a 10 year cohort.
P309 Withdrawal of thiopurines in Inflammatory Bowel Disease patients in stable remission: a prospective, multicentre cohort study
P310 Atopic dermatitis is associated with the clinical course of Inflammatory Bowel Disease
P311 Depression and anxiety are associated with poor clinical outcomes in Inflammatory Bowel Disease : A Nationwide Population-Based Study in South Korea
P312 Combination corticosteroids with 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: A multi-center randomized controlled trial
P313 Within 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses
P314 Elderly onset is associated with low efficacy of anti-TNF treatment in Bio-naïve IBD patients: A multicenter cohort study by the Osaka Gut Forum
P315 High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study
P316 Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North
P317 Ustekinumab Trough Concentrations Associated with Biochemical Outcomes in Patients with Crohn’s Disease
P318 Safety of Biological Therapies in Elderly IBD: a Systematic Review and Meta-analysis
P319 Incorporating HLADQA1*05 in pre-biologic screening in IBD patients initiating biologic therapies
P320 6-Thioguanine nucleotide levels are associated with trough levels of infliximab and adalimumab in Inflammatory Bowel Disease patients on combination therapy: A retrospective multicentre study
P321 Mucosal Healing and Clinical remission after Treatment with Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA study): final results from a prospective, open-label, single-arm study
P322 Effectiveness of Tumor Necrosis Factor-alpha inhibitors and Thiopurines combination therapy according to 6-thioguanine nucleotides plasma levels: A Systematic Review.
P323 The Crohn's Disease Exclusion Diet (CDED) for pouch inflammation: an interventional pilot study
P324 Tacrolimus for induction of remission in refractory ulcerative colitis: a Cochrane systematic review
P325 Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn's disease
P326 The effect of compliance during exclusive enteral nutrition on faecal calprotectin levels in children with Crohn’s disease
P327 Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoring
P328 In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease
P329 Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patients
P330 Immunity in patients with inflammatory bowel disease on biologic therapy after COVID 19 vaccination
P331 Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies
P331 Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies
P332 Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).
P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach
P334 Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort.
P335 Utility of Intestinal Ultrasound in Monitoring Disease Activity in Ulcerative Colitis Patients Treated with Biologics
P336 Can Mesenchymal Stem Cell (MSC) apoptosis be used as a biomarker for treatment success in perianal fistulising Crohn’s Disease (pCD)? Findings from a prospective pilot study
P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum
P338 Early proactive drug monitoring strategy of infliximab as monotherapy for inflammatory bowel disease in paediatric patients is associated with good sustained clinical remission
P339 Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with Inflammatory Bowel Disease
P340 Risankizumab in Crohn's disease: Real World Experience from a Pre-Approval Access Program
P341 Pharmacokinetics and exposure-response analyses of upadacitinib in patients with moderate to severe ulcerative colitis – Analyses of induction and maintenance clinical trials
P342 Trans-continental analysis of over 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium
P343 Changing the coUrse of cRohn’s disease with an Early use of adalimumab: The CURE study from the GETAID
P344 What our patients are looking for - the common fields of interest in IBD patients: A Google Trends Analysis
P345 The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn’s Disease
P346 Chronic pouch failure rates after close rectal dissection and total mesorectal excision in ileal pouch-anal anastomosis.
P347 Sarcopenia is a poor prognostic factor for endoscopic outcomes in patients with Crohn’s disease
P348 Top down versus step-up strategies to prevent postoperative recurrence in Crohn’s disease
P349 Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU).
P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study.
P351 Allogenic adipose-derived mesenchymal stem cells (darvadstrocel) in Japanese patients with complex perianal fistulas in Crohn’s disease
P352 Ustekinumab is associated with superior treatment persistence compared to vedolizumab in Crohn’s disease patients who failed to anti-TNF therapy: results from a Hungarian cohort study
P353 Agreement between patients, senior and junior physicians on disease activity and burden scoring in inflammatory bowel disease, using a tele-monitoring platform
P354 Immunological response to vaccination against SARS-COV-2 infection in Inflammatory Bowel Disease patients under immunosuppressive therapy: should we prioritize an additional booster injection?
P355 Exceeding treatment expectations in Crohn's disease: transmural healing and a new definition of deep remission
P356 Czech experience with treatment of Crohn´s disease perianal fistulas by allogenic mesenchymal stem cell
P357 Monitoring of Thiopurines and Methotrexate in Inflammatory Bowel Disease: Are we Monitoring Too Frequently? A Cross Sectional Study.
P358 Keeping it simple: How a streamlined referrals process reduces the time taken to initiate biologic therapy
P359 Radiomics could predict surgery at 10 years in Crohn’s disease
P360 The correlation between ophthalmological posterior segment findings and disease severity in patients with inflammatory bowel disease
P361 PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis
P362 Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring.
P363 Are clinical decision support tools for vedolizumab and ustekinumab in biologic naïve patients with Crohn’s disease drug-specific?
P364 Comparison of two treatment strategies in IBD: Biosimilar adalimumab (CinnoRA®) in monotherapy and in combination with azathioprine
P365 Weight gain after initiation of adalimumab in patients with Crohn’s disease
P366 Exclusive enteral nutrition drives protective microbiome modulation in paediatric Crohn's Disease
P367 quality of life in patients with Inflammatory Bowel Disease
P368 Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center
P369 Dual Biologic in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series
P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase 3 study U ACHIEVE maintenance
P372 Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn`s disease
P373 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety
P374 Front loading infliximab dosing regimen improves outcomes in Crohn’s Disease perianal fistulas
P375 Faecal calprotectin variation after induction therapy with infliximab to predict clinical, endoscopic and ultrasonographic remission in Crohn’s disease patients
P376 Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome
P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study
P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open
P379 Trends in Colectomy Rates and Biologic use over a 30-year period: What has changed?
P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease
P381 Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis
P382 Novel Image Enhanced Endoscopy (IEE) technologies for surveillance of colonic Inflammatory Bowel Disease: A pilot study evaluating Texture and Colour Enhancement Imaging (TXI) and Linked Colour Imaging (LCI) as compared with chromoendoscopy.
P383 Ustekinumab as an opportunity for refractory Ulcerative Colitis patients.
P384 Postoperative Endoscopic Recurrence In Patients With Crohn’s Disease After “Curative” Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
P385 Tailoring induction treatment for children with Crohn’s disease.
P386 Predictive models for assessing the response to ustekinumab in Crohn’s disease patients
P387 Rapid Implementation of an Evidence-Based, Virtual COVID-19 Vaccine Education Clinic at the Nova Scotia Collaborative Inflammatory Bowel Disease Clinic (NSCIBD) Program
P388 Asking teenagers and young adults with IBD; “what matters to you?”. A qualitative survey during the COVID-19 pandemic
P389 Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom
P390 Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn´s disease: multicentric experience in the Basque Country and Navarre
P391 Unpacking the different popular diets for pediatric Crohn's disease - concerns around nutritional adequacy
P392 To study the prevalence of depression and anxiety in patients of Inflammatory Bowel Disease (IBD) and the efficacy of psychopharmacotherapy in these patients: A pilot study
P393 Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis.
P394 A prospective analysis of body composition in patients with Inflammatory Bowel Disease and changes during biologic therapy
P395 Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with Infliximab
P396 COVID-19 pandemic-related endoscopy delays did not translate to deleterious outcomes for patients with Inflammatory Bowel Disease: A retrospective cohort study
P397 Can upskilling pharmacy technicians support a robust and cost-effective Inflammatory Bowel Disease patient review process? A single-centre prospective study.
P398 Long term efficacy and safety of ABP 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study
P399 C-Reactive Protein Values After Surgery for Inflammatory Bowel Disease: Is It Still A Good Marker For Intra-Abdominal Complication? A Retrospective Cohort Study of 347 procedures.
P400 Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
P401 Tofacitinib tissue exposure correlates with endoscopic outcome
P402 Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical program
P403 The role of Organic Cation Transporter (OCTN)-1 in predicting individual response to therapy in Ulcerative Colitis: towards a personalized approach.
P404 Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials
P405 Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn’s Disease – preliminary results from the Danish IBD Biobank Project
P406 Disease clearance in patients with ulcerative colitis treated with aminosalicylates
P407 A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: An interim analysis
P408 Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis
P409 FMT induced increase in gut microbial diversity and Clostridia is associated with clinical response in patients with ulcerative colitis – results from STOP Colitis trial
P410 safety of biological drugs for inflammatory bowel disease in elderly patients
P411 Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program
P412 Drug persistence and endoscopic, histologic and biochemical remission rates among patients following ileal pouch-anal anastomosis treated with biologic therapy: Results from a prospective patient cohort.
P413 Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b2 vaccines in the immunosuppressed (RESCUE)
P414 Stoma in patiens with IBD: friend or foe? -\tEffect of stoma on course of disease, psychological well-being and working capacity
P415 Improving food‐related quality of life in Inflammatory Bowel Disease with a novel web-based intervention: a randomised controlled feasibility trial
P416 Addition of oral antibiotics to mechanical bowel preparation significantly improves anastomotic healing after ileocolic resection for Crohn’s disease
P417 Seroconversion after COVID-19 Vaccination in Inflammatory Bowel Disease Patients
P418 Development and validation of a digital health platform (IBD NutriCare) for telenutrition in patients with Inflammatory bowel disease
P419 Long-term outcome of ulcerative colitis in pediatric patients who achieved mucosal and histological healing: a real-life referral center experience
P420 Long term efficacy of ustekinumab in Crohn's disease patients after vedolizumab failure
P421 Correlation of bowel activity parameters in intestinal ultrasound to drug retention and trough drug levels in Crohn's disease
P422 How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?
P423 Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries.
P424 Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations
P425 Rates of tuberculosis infection in Crohn’s Disease patients before and during anti-tumor necrosis factor therapy
P426 Association Between vedolizumab therapy outcome and Pre-treatment DUBLIN Score & CRP-Albumin Ratio in Ulcerative Colitis
P427 Exploring phenotype and treatment of inflammatory bowel disease in the elderly
P428 A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory Crohn’s colitis: A preliminary analysis
P429 Mesalazine has no place in the treatment of Crohn's disease. Really?
P430 Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study
P431 Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trial
P432 Relationship between haemoglobin status and utility in patients with iron deficiency anaemia in inflammatory bowel disease: A post-hoc analysis of a phase 3 clinical trial
P433 Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.
P434 The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
P435 High rate of vitamin deficiencies in patients after total proctocolectomy and pouch surgery- results from a prospective cohort
P436 Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
P437 Reoperations and long-term survival of Kock’s continent ileostomy in Inflammatory bowel disease patients: a population based national cohort study from Sweden.
P438 The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age.
P439 Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease.
P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis.
P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease.
P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis
P443 Trough concentration response in infliximab and adalimumab treated children with IBD following treatment adjustment: A pharmacokinetic model.
P444 COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort
P445 Is objective disease monitoring strategy tailored to the presence of clinical symptoms, a prospective cohort study from a tertiary IBD center from Hungary
P446 Long-term Clinical Effectiveness And Stoma Outcome Of Fecal Diversion In Refractory Crohn’s Proctitis
P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease
P448 Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
P449 Autologous fat graft injection for the treatment of perianal fistulas in Crohn’s disease: A systematic review and single-arm meta-analysis
P450 Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease
P451 Evaluating drug sustainability, efficacy and safety of biologic agents in elderly patients with Inflammatory Bowel Disease: a single center retrospective study
P452 Tofacitinib Effectiveness and Safety as Therapy for Ulcerative Colitis
P453 Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease
P454 Evaluation of the nutritional care status in italian centers managing patients affected by inflammatory bowel disease
P455 Aminosalicylates in Ulcerative Colitis: old but gold?
P456 Risk of malignant tumors in patients with autoimmune diseases on ustekinumab therapy: a systematic review and meta-analysis
P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis
P458 Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn's disease (the SPEED-UP study) - A multi-center study from the paediatric IBD Porto group of ESPGHAN
P459 High inadequate surveillance rates in colitis-associated advanced neoplasia: a multicenter retrospective cohort study
P460 A Real-World Picture of Adverse Drug Reactions in Inflammatory Bowel Disease
P461 COVID-19 outcomes in patients receiving anti-TNF treatments: A systematic review and meta-analysis
P462 Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response
P463 Serum and mucosal Serpin E1 concentration correlates with endoscopic activity in inflammatory bowel disease - potential new activity marker
P464 Rac1/pSTAT3 expression in T lymphocytes: A potential pharmacodynamic marker for thiopurines in the treatment of Inflammatory Bowel Disease patients?
P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?
P466 Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice
P468 Evaluation of work productivity and activity impairment in moderate-to-severe ulcerative colitis participants treated with ozanimod in the phase 3 True North study
P469 Infliximab for induction of medically-induced remission in Crohn's disease: a Cochrane systematic review
P470 Real-world characteristics and complications of patients with Ulcerative Colitis receiving conventional therapy in the public healthcare system in Brazil
P471 Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naïve and biologic exposed patients
P472 Changes in colectomy for Ulcerative Colitis during the last two decades: an in-depth retrospective analysis
P473 Real world experience with the Crohn's Disease Exclusion Diet (CDED) in a tertiary IBD clinic
P474 Prevalence of fecal incontinence and clinical characteristics of IBD patients in remission and treated with biologics – experience from a tertiary referral center
P475 Profiling the use of Complementary Alternative Medicines among IBD patients
P476 Disease recurrence patterns in patients undergoing bowel resections for Crohn’s disease.
P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open
P478 The role of proactive measurement of adalimumab trough levels and antibodies to adalimumab in Greek patients with Inflammatory Bowel Disease
P479 Trends in medication use and treatment patterns in Chinese patients with Inflammatory Bowel Diseases: A multicenter cohort study from 1999 to 2020
P480 Comparison of executive functioning profiles among adults with Crohn's disease and Ulcerative colitis
P481 profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease
P482 Pre-screening IBD patients starting biologic therapies, a positive single centre quality improvement project
P483 Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar
P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
P485 Apolipoprotein C3 is Downregulated in Patients with Inflammatory Bowel Disease
P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials
P487 Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
P488 Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM® MarketScan®
P489 Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study.
P490 Patients with inflammatory bowel disease should be vaccinated against pneumococcus and influenza despite immunosuppressive therapy
P491 Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE
P492 A comparison of treatment effects for clinical, endoscopic and histological remission in ulcerative colitis clinical trials
P493 The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study
P494 A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.
P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials
P496 Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study
P497 Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis
P498 Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess: The Leeds Steroids study
P499 Accessing ultrasonographic transmural healing in patients with Crohn’s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels?
P500 The use of budesonide results in lower risk for infections compared to systemic glucocorticoids
P501 Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort study
P502 Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from China
P503 Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn's disease: A multi-centre prospective cohort study
P504 Prospective analysis of micronutrient status and disease course in Inflammatory Bowel Disease
P505 Smoking is associated with the development of adverse events of biological therapy in patients with Inflammatory Bowel Disease
P506 Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany
P507 Need for surgery in patients with ulcerative colitis in the era of biologic therapy.
P508 The impact of disease duration and early biologic treatment on transmural healing in Crohn’s disease
P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease
P510 Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease; Systematic Review and Network Meta-analysis
P511 Efficacy of Crohn's Disease exclusion diet in different clinical scenarios in paediatrics; at onset of the disease and after loss of response to biological therapy
P512 Vedolizumab is effective in the prevention and treatment of postoperative recurrence in patients with Crohn´s disease
P513 Treatment persistence in bio-naive patients with long-standing Crohn's disease treated with first-line biologics: real-life data from a Croatian tertiary center.
P514 Optimising response to infliximab in the management of perianal Crohn’s disease
P515 Inflammatory bowel disease and malignancy – the outcome of patients with malignancy diagnosed before IBD diagnosis or IBD-targeted therapy
P516 Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study
P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
P518 Partial enteral nutrition use for Crohn’s disease management: a systematic review
P519 Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
P520 Very early intestinal ultrasound predicts intravenous corticosteroid failure in hospitalized severe ulcerative colitis patients
P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenanc
P522 Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 Program
P523 effectiveness of biological treatments for inflammatory bowel disease in the elderly patients
P524 Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn's disease.
P525 A prospective interventional study to evaluate the effect of hypoxia on healthy volunteers and patients with inflammatory bowel disease: The altitude IBD study
P526 Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patients
P527 Telemedicine in IBD patients: results of a national survey of the Italian IBD patients’ association (AMICI Onlus)
P528 Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBD
P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID).
P530 Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysis
P531 Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic region
P532 Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels
[
1
]
2
>
>>
About ECCO
ECCO General Assembly
ECCO Governing Board
The Council of National Representatives
Solidarity for Ukraine
ECCO Operational Board / Committees
Committee Podcasts
Affiliate ECCO Societies & ECCO Partners
ECCO Office
ECCO Disclosures
ECCO Elections
Congresses & Events
Future
19th Congress of ECCO 2024 - Stockholm
Past
18th Congress of ECCO 2023 - Copenhagen
Event Calendar
Quality Assurance/Endorsement
Congress Statistics
Membership
Individual Membership
Country Members
Corporate Membership
Affiliate ECCO Societies
Education
E-QUALITY
e-CCO Learning
Educational Workshops
Congress Educational Programme
IBD Nurse Education Programme
Y-ECCO Mentorship Forum
Letters from the e-Learning Ambassador
Science
UR-CARE
The Reviewers of ECCO
The Reviewers of 2022
Fellowships and Grants
ECCO Young Researcher Award
Scientific Workshops
Research Projects
BIOCYCLE Dissemination Workshops
ECCO CONFER Cases
Job postings
Publications
JCC
ECCO Guidelines
ECCO Topical Review
ECCO Position Statements
ECCO Scientific Workshop Papers
ECCO News
ECCO IBD App
ECCO Congress Abstracts
Surveys
Other publications
COVID-19
20years Anniversary Book
eNewsletter